The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Transcriptional Programming Research, & a Twist on CAR-T Cell Therapy

Transcriptional Programming Research, & a Twist on CAR-T Cell Therapy

March 17, 2018 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF
A genetically engineered T cell.

A genetically engineered T cell.

SAN DIEGO—At the 2017 ACR/ARHP Annual Meeting this past November, an expert said researchers are making progress in identifying drugs that can correct problems with transcriptional programming, which, if perfected, could go a long way toward harnessing more fully the power of genetics knowledge and directing it toward patient care. The session also delved into how researchers are working to apply a strategy similar to chimeric antigen receptor (CAR) T cell therapy to autoimmune disorders.

You Might Also Like
  • Lupus B Cell Research Points Toward Targeted Therapies
  • ACR/ARHP Annual Meeting 2012: New Research Into Stem Cell Therapy and Drugs May Lead to Breakthrough Treatments for Osteoarthritis
  • Research Identifies Two New Cell Types in Sjögren’s Syndrome
Explore This Issue
March 2018
Also By This Author
  • 2015 ACR/ARHP Annual Meeting: Insights into the Microbiome

Controlling Transcription

Most of the genetic variants identified in genome-wide association studies (GWAS) map to noncoding DNA, and there’s a growing understanding that the vast majority of this noncoding DNA involves gene enhancers and repressors that can regulate transcriptional programs, said Dennis Carson, MD, professor of medicine at the University of California, San Diego.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“We do not yet have methods to identify drugs that can modify and, hopefully, correct aberrant transcriptional programs,” he said. “This is what we’re taking a stab at in our lab.”

Dr. Carson has pursued this line of research for a decade. The challenge, in part, is that what’s encoded are not proteins, and the enhancer or repressor effect depends on the cellular context, so organism-wide targeting could produce undesirable effects. Plus, multiple enhancers and repressors work together in complex ways to control the transcriptional programs.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Carson’s center has approached the problem with a high-throughput process to examine how drugs or compounds regulate the transcriptional response when a stimulus is applied.

“Our idea was you might be able to find improved approaches for the discovery of immune regulatory drugs by looking at drugs or compounds that regulate the magnitude of transcriptional response to a stimulus, the kinetics of a transcriptional response and breadth of a transcriptional response,” he said.

Using biochemical and computational methods, the researchers look for compounds that act either as an immune enhancer and slow the response to the stimulus, or as an immune repressor and speed it up—all without affecting the basic physiology of the response. They’ve looked at the NF-kappa-beta and interferon pathways.1

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

To pare down the compounds to legitimate contenders, the researchers first focused on those that feature kinetics similar to other compounds and might hit the same target, and that have similar chemical structures to others, making it much more statistically likely they’re true hits. Then researchers moved to RNA sequencing to further validate the compounds.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Meeting Reports Tagged With: ACR/ARHP Annual Meeting, pemphigus vulgaris, T cell receptor, transcriptional programmingIssue: March 2018

You Might Also Like:
  • Lupus B Cell Research Points Toward Targeted Therapies
  • ACR/ARHP Annual Meeting 2012: New Research Into Stem Cell Therapy and Drugs May Lead to Breakthrough Treatments for Osteoarthritis
  • Research Identifies Two New Cell Types in Sjögren’s Syndrome
  • Turbocharge Your Cell Analysis with Mass Cytometry

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.